Company / Cost of Revenue
Corcept Therapeutics Incorporated Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$13.0M
FY2025
5-year range
$5.5M / $13.0M
FY2021-FY2025
Trend
+19.3%
vs FY2024
Sector context
#69 of 85
Health Care
What the data says
Corcept Therapeutics Incorporated's cost of revenue of $13M is lower than 81% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 7 consecutive years, from $2M in FY2018 to $13M in FY2025.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of +20.0%.
Increased from $6M to $13M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +32.5%
- 5-Year CAGR
- +20.0%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 85This company $13.0M Sector average $2.0B
▼
-99.3% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's cost of revenue has grown for 7 consecutive years.
- 5-year CAGR of +20.0%, indicating consistent growth.
- In FY2025, cost of revenue increased 19.3% year-over-year.
- Ranks #69 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.0M | +19.3% |
| FY2024 | $10.9M | +67.9% |
| FY2023 | $6.5M | +16.1% |
| FY2022 | $5.6M | +1.4% |
| FY2021 | $5.5M | +5.5% |
| FY2020 | $5.2M | +46.7% |
| FY2019 | $3.6M | +72.7% |
| FY2018 | $2.1M | -42.1% |
| FY2017 | $3.6M | +302.9% |
| FY2016 | $882.0K | -35.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026